Xct inhibitor - J-Pharma
Latest Information Update: 18 Mar 2025
At a glance
- Originator J-Pharma
- Class
- Mechanism of Action SLC7A11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 06 Jan 2025 Early research in Unspecified in Japan (PO), before December 2024 (J-Pharma pipeline, December 2024)